MBII - MBII STOCK NEWS

Marrone Bio Innovations (NASDAQ: MBII) will announce its Q3 2021 financial results on November 10, 2021, after market close. An investor conference call will take place at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested participants can join via U.S. dial-in at 1-844-612-2103 or internationally at 1-918-922-3145, using conference ID 2099126. The company focuses on sustainable agricultural solutions and boasts a strong portfolio of products and patents.

Marrone Bio Innovations (NASDAQ: MBII) is advancing three bioherbicides into late-stage development, targeting the $27 billion weed control market. CEO Kevin Helash emphasized the pressing need for sustainable herbicide alternatives amidst rising weed resistance. The bioherbicides, MBI-005, MBI-011, and MBI-014/015, show promise with MBI-014/015 being 50-to-100 times more effective than leading chemical counterparts. The company relies on a diverse microbial library, potentially leading to further innovations. These advancements position Marrone Bio as a leader in sustainable agricultural solutions.

Marrone Bio Innovations (NASDAQ: MBII) announced plans to submit MBI-306, a new nematicide/insecticide, to U.S. regulatory authorities soon. The product targets global markets for row and specialty crops and is projected to generate over $100 million in peak incremental revenue. Concurrently, it prepares to submit MBI-206, a bionematicide seed treatment, to Brazil, increasing its footprint in significant agricultural markets. Both products have strong efficacy and climate impact ratings, with expected commercial launches in 2023/2024.

Marrone Bio Innovations (NASDAQ: MBII) reported its second-quarter financial results for 2021, showing a net loss of $3 million, up 6% from the previous year, while Adjusted EBITDA improved by 51% to a loss of $0.7 million. Revenues rose 3% to $12.6 million, despite challenges from adverse weather and supply chain issues. Gross profit increased by 5%, yielding gross margins of 61.7%, marking the 11th consecutive quarter above 50%. For the first half, net losses decreased by 36%, with revenues up 8% to $23.6 million, driven by strong sales in the U.S.

Marrone Bio Innovations (NASDAQ: MBII) announces a strategic partnership with Terramera to enhance sustainable crop protection. The collaboration aims to integrate MBI's biological products with Terramera's Actigate™ technology and AI-driven screening platform. This synergy is expected to expedite product development and improve performance in MBI's portfolio, including products like Regalia® Biofungicide and Venerate® XC Bioinsecticide. Field trials of the combined products are scheduled for late summer and early fall 2021, indicating a proactive approach to innovation in agricultural practices.

Marrone Bio Innovations, trading under the ticker MBII, will release its second quarter financial results on August 16, 2021, after market close. The conference call is scheduled for the same day at 4:30 p.m. ET, with an opportunity for Q&A. Investors are encouraged to dial in 10 minutes early to ensure participation. The call will be available for playback until September 1, 2021. Marrone Bio Innovations focuses on sustainable agriculture through biological products for crop protection, with over 15 products and more than 500 patents supporting its market presence.

Marrone Bio (NASDAQ: MBII) has expanded its partnership with Rizobacter to distribute Rizonema™, a biological seed treatment for nematodes and soil insects, in Brazil. Following multiple successful regulatory trials, MBI plans to enhance the product label for broader pest control, targeting cotton and additional nematodes. The Brazilian seed treatment market is projected to reach $1.27 billion by 2024, with biological options expected to grow at a 10.4% CAGR. This collaboration is strategically important as Brazil leads in soybean production and presents significant market opportunities for sustainable agricultural solutions.

Marrone Bio Innovations (MBII) has partnered with ATP Nutrition to distribute Stargus Biofungicide for broad acre crops in Canada, targeting canola, beans, peas, soybeans, and sunflowers. This venture taps into a rapidly growing biocontrol market projected to grow at a CAGR of 12-15%. The product, based on a patented strain of Bacillus bacteria, combats common diseases like white mold. The collaboration aims to enhance distribution efficiencies and meet farmers' demand for sustainable crop disease management solutions.

Marrone Bio Innovations (NASDAQ: MBII) reported its Q1 2021 results, marking its 11th consecutive quarter of revenue growth and 10th consecutive quarter of gross margins exceeding 50%. Operating expenses fell by 11%, maintaining a 91% ratio to sales. The company expects revenue growth in the upper 20% range for 2021 and aims for positive Adjusted EBITDA. Key growth drivers include expansion in seed treatments and new product launches in Europe, with an anticipated market presence on 35 million acres in 2021.